0000905148-20-000880.txt : 20200812 0000905148-20-000880.hdr.sgml : 20200812 20200812210018 ACCESSION NUMBER: 0000905148-20-000880 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200811 FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P. CENTRAL INDEX KEY: 0001634632 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 201096834 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic GP II, L.P. CENTRAL INDEX KEY: 0001729409 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 201096835 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic GP II, Ltd. CENTRAL INDEX KEY: 0001729408 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 201096836 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOODMAN COREY S CENTRAL INDEX KEY: 0001278411 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 201096837 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Adelman Robert J CENTRAL INDEX KEY: 0001329161 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 201096838 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001651431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364813934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 978-503-2124 MAIL ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 form4.xml X0306 4 2020-08-11 0001651431 Checkmate Pharmaceuticals, Inc. CMPI 0001634632 venBio Global Strategic Fund II L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001729409 venBio Global Strategic GP II, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001729408 venBio Global Strategic GP II, Ltd. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001278411 GOODMAN COREY S 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001329161 Adelman Robert J 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true Common Stock 2020-08-11 4 C 0 3473374 A 3473374 D Common Stock 2020-08-11 4 P 0 200000 15 A 3673374 D Series A Preferred Stock 2020-08-11 4 C 0 12500000 0 D Common Stock 1671771 0 D Series B Preferred Stock 2020-08-11 4 C 0 8753350 0 D Common Stock 1314165 0 D Series C Preferred Stock 2020-08-11 4 C 0 3644624 0 D Common Stock 487438 0 D The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2020-08-12 venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 2020-08-12 venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 2020-08-12 Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact 2020-08-12 Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 2020-08-12